Sale!

Controversies in the Treatment of Lung Cancer 12th International Symposium on Special Aspects of Radiotherapy Berlin October 2008 Frontiers of Radiation Therapy and Oncology 1st Edition by Heide, Schmittel, Kaiser, Hinkelbein 3805592981 9783805592987

Original price was: $50.00.Current price is: $35.00.

Controversies in the Treatment of Lung Cancer 12th International Symposium on Special Aspects of Radiotherapy Berlin October 2008 Frontiers of Radiation Therapy and Oncology 1st Edition J. Heide Digital Instant Download

Author(s): J. Heide, A. Schmittel, D. Kaiser, W. Hinkelbein
ISBN(s): 9783805592987, 3805592981
Edition: 1
File Details: PDF, 3.24 MB
Year: 2009
Language: english
SKU: EB-1863574 Category: Tags: , , ,

Controversies in the Treatment of Lung Cancer 12th International Symposium on Special Aspects of Radiotherapy Berlin October 2008 Frontiers of Radiation Therapy and Oncology 1st Edition by Heide, Schmittel, Kaiser, Hinkelbein – Ebook PDF Instant Download/Delivery: 3805592981, 9783805592987

Full download Controversies in the Treatment of Lung Cancer 12th International Symposium on Special Aspects of Radiotherapy Berlin October 2008 Frontiers of Radiation Therapy and Oncology 1st Edition after payment

 

Product details:

ISBN 10: 3805592981 

ISBN 13: 9783805592987

Author: J. Heide, A. Schmittel, D. Kaiser, W. Hinkelbein

Under the auspices of the 12th International Symposium on Special Aspects in Radiotherapy 2008 in Berlin, acknowledged experts presented their perspectives on small and non-small cell lung cancer, reflecting the latest standards and engaging in controversies in the diagnosis and treatment of this disease. In the first part of this volume, aspects of the diagnostic workup are highlighted from the histopathologist’s point of view, followed by presentations concerning the value of PET-CT and whole-body MRI in the staging of lung cancer. The use and current methods in bronchoscopy, endoscopic ultrasound, video-endoscopy and mediastinoscopy are discussed in detail. The second section presents surgical and radio-oncological treatment concepts for stage I/II non-small cell lung cancer including stereotactic radiotherapy. The third section outlines the curative options for stage III NSCLC: extended surgical approaches , definitive radiochemotherapy and current concepts in adjuvant therapies. Emphasis is also placed on altered fractionation schemes in radiotherapy. Section 4 is dedicated to palliative procedures and the last section gives an in-depth presentation of small cell lung cancer. This book provides an excellent overview of up-to-date standards and future strategies in lung cancer treatment. It will be of great value to surgeons, radiation oncologists, pulmonary specialists and other clinicians interested in this disease.

Table of contents:

  1. Tumor Size: An Essential Prognostic Factor in Lung Cancer
  2. Small Cell Lung Cancer
  3. Prognosis and Predictive Factors in Small Cell Lung Cancer
  4. Histological Subtype: A Prognostic Factor in NSCLC
  5. Squamous Cell Carcinoma Histological Subtypes Associated with Poor Prognosis
  6. Adenocarcinoma Histological Subtypes Associated with Poor Prognosis
  7. Bronchioloalveolar Cell Carcinoma Growth Pattern: A Favorable Prognostic Factor
  8. Large Cell Carcinomas
  9. Prognostic Implication of Molecular Markers
  10. EGFR and K-RAS in Lung Cancer
  11. Prognostic Implication of Excision Repair Cross-Complementing I
  12. Prognostic Implication of Ribonucleotide Reductase M1
  13. Prognostic Implication of Thymidylate Synthase
  14. Conclusion
  15. References
  16. FDG-PET/CT in Lung Cancer: An Update
  17. Abstract
  18. Non-Small Cell Lung Cancer
  19. Imaging Modalities
  20. Lung Nodules
  21. Morphological Imaging
  22. [18]F-Fluorine Deoxyglucose PET
  23. Lymph Node Staging
  24. Staging of Lung Cancer- Distant Metastases
  25. Morphological Imaging
  26. FDG-PET
  27. Recurrence Detection
  28. Molecular (Metabolic) Radiation Therapy Planning
  29. Prediction and Monitoring Response to Therapy
  30. Pleural Metastases
  31. Cost-Effectiveness
  32. Small Cell Lung Cancer
  33. References
  34. Whole-Body Magnetic Resonance Imaging for Staging of Lung Cancer
  35. Abstract
  36. Technical Aspects of Whole-Body MRI
  37. Staging of Lung Cancer Using Whole-Body MRI
  38. Conclusions
  39. References
  40. Bronchoscopy/Endobronchial Ultrasound
  41. Abstract
  42. EBUS-TBNA: Technique
  43. Clinical Results
  44. Complications
  45. Conclusion
  46. References
  47. New Developments in Videomediastinoscopy: Video-Assisted Mediastinoscopic Lymphadenectomy and Mediastinoscopic Ultrasound
  48. Abstract
  49. Methods
  50. Results
  51. Comments
  52. Implications for Clinical Practice and Further Research
  53. References
  54. Resection in Stage I/II Non-Small Cell Lung Cancer
  55. Abstract
  56. Surgery in Stages I and II
  57. Lobectomy
  58. Sleeve Resection
  59. Limited Resection
  60. Resection of Stage I and II NSCLC in Aged Patients
  61. Conclusion
  62. References
  63. Role of Mediastinal Lymph Node Dissection in Non-Small Cell Lung Cancer
  64. Abstract
  65. Surgical Technique of Systematic Lymph Node Dissection
  66. Role of Nodal Involvement on Survival
  67. Impact of Mediastinal Lymph Node Dissection on Operative Morbidity, Mortality and Quality of Life
  68. Diagnostic Role of Mediastinal Lymph Node Dissection
  69. Therapeutic Role of Mediastinal Lymph Node Dissection
  70. Conclusion
  71. References
  72. Radiation Therapy for Early Stage (I/II) Non-Small Cell Lung Cancer
  73. Abstract
  74. Radiation Therapy alone in Early Non-Small Cell Lung Cancer
  75. Avenues for an Improvement of RT Alone in Early NSCLC
  76. References
  77. Stereotactic Body Radiation Therapy for Early Non-Small Cell Lung Cancer
  78. Abstract
  79. Definitions of Stereotactic Body Radiation Therapy
  80. Staging Procedures before SBRT
  81. Implementation of Techniques in Clinical Routine
  82. Biological Basis of Hypofractionated SBRT
  83. Historical Aspects and Early Clinical Experience in SBRT of Lung Cancer
  84. Clinical Experience
  85. Local Tumor Response
  86. Survival Data
  87. Side Effects
  88. Comparison of SBRT with Surgical Data
  89. Follow-Up Recommendations
  90. Future
  91. References
  92. Extended Surgical Resection in Stage III Non-Small Cell Lung Cancer
  93. Abstract
  94. Discussion of Stage-Related Treatment
  95. Stage IIIA
  96. Stage IIIB
  97. Conclusions
  98. References
  99. Stage III: Definitive Chemoradiotherapy
  100. Abstract
  101. Optimization of Combined Radiotherapy and Chemotherapy
  102. Which Chemotherapy and Radiotherapy Regimens Are Optimal for Concurrent Chemoradiotherapy?
  103. How Do Comorbidities Influence the Performance of Concurrent Chemoradiotherapy?
  104. References
  105. Adjuvant Therapy in Early-Stage Non-Small Cell Lung Cancer
  106. Abstract
  107. Landmark Studies Concerning Adjuvant Platinum-Based Chemotherapy
  108. Negative Studies
  109. The LACE (Lung Adjuvant Cisplatin Evaluation) Meta-Analysis (table 2)
  110. Survival
  111. Toxicity
  112. Compliance to Therapy
  113. Postoperative Radiotherapy (PORT)
  114. Stages
  115. Adjuvant Chemotherapy and Stage (table 3)
  116. Which Chemotherapy Combination?
  117. Adjuvant Radiotherapy
  118. Patient Selection and Predictive or Prognostic Factors
  119. Age
  120. Performance Score 2
  121. ERCC1 (Excision Repair Cross-Complementation Group 1)
  122. Other Biomarker Studies
  123. Neoadjuvant Chemotherapy
  124. Conclusion
  125. References
  126. Postoperative Irradiation in Non-Small Cell Lung Cancer
  127. Abstract
  128. References
  129. Altered Fractionation Schemes in Radiotherapy
  130. Abstract
  131. Hypofractionated Stereotactic Body Radiotherapy for NSCLC (Stage I)
  132. Hyperfractionated Accelerated Radiotherapy for Stage III NSCLC
  133. References
  134. Chemotherapy of Advanced Non-Small Cell Lung Cancer
  135. Abstract
  136. Pemetrexed
  137. Cisplatin- vs. Carboplatin-Based Chemotherapy
  138. Elderly Patients and Patients with Reduced Performance Status
  139. Customized Chemotherapy
  140. Targeted Therapies
  141. Maintenance Therapy
  142. Systemic Chemotherapy in Patients Progressing after First-Line Chemotherapy
  143. Assessment of Efficacy
  144. References
  145. Radiotherapy
  146. Abstract
  147. Clinical Manifestations of Advanced Lung Carcinoma
  148. Palliative Potential of Radiotherapy
  149. Treatment Strategies
  150. References
  151. Treatment of Limited Disease Small Cell Lung Cancer
  152. Abstract
  153. Thoracic Radiotherapy
  154. (1) What is the Optimal Radiation Dose and Fractionation?
  155. (2) What Are the Target Volumes?
  156. (3) What Is the Best Timing, Sequencing and Overall Treatment Time?
  157. Patient Selection
  158. Future Perspectives
  159. References
  160. Radiochemotherapy in Extensive Disease Small Cell Lung Cancer ED-SCLC
  161. Abstract
  162. RT in ED-SCLC Trial
  163. Future Approaches
  164. Conclusions
  165. References
  166. Radiotherapy for Extensive Stage Small Cell Lung Cancer
  167. Abstract
  168. Introduction
  169. Brain Metastases
  170. Prophylactic Cranial Irradiation
  171. Thoracic Radiotherapy
  172. References
  173. Controversies in the Treatment of Advanced Stages of Small Cell Lung Cancer
  174. Abstract
  175. First-Line Chemotherapy
  176. Prophylactic Cranial Irradiation after First-Line Chemotherapy
  177. Second-Line Chemotherapy
  178. References
  179. Complementary and Alternative Medicine in Lung Cancer Patients: A Neglected Phenomenon?

People also search:

controversies in lung cancer

consequences of lung cancer

controversies about cancer

lung cancer treatment history

what are the consequences of lung cancer

Tags: Heide, Schmittel, Kaiser, Treatment, Controversies